Category
6 articles
Unvalidated antibodies rarely announce themselves as procurement failures. They reappear as irreproducible blots, wasted technician hours and grant milestones that cannot be defended. This article sets out a practical validation and lot-tracking framework for UK research teams buying reagents in 2026.
Home-sampling kits are moving into mainstream UK diagnostics, but a validation pack that stops at the laboratory bench leaves the most variable preanalytical step unexamined. This article sets out a practical transport-stability protocol for blood and saliva kits, from Royal Mail transit profiles to acceptance criteria and the documentation commissioners will expect.
Requests to train AI models on biobank tissue and data expose a gap between broad research consent and machine-learning reuse. This release audit sets out the provenance, commercial-use, re-identification and model-documentation checks UK biobanks should complete before samples leave the freezer.
Vendor throughput claims are measured on a laboratory that does not exist. The informal workarounds and invisible handoffs that hold a real NHS pathology service together are the missing specification — and two weeks of structured observation is cheaper than buying the wrong machine.
A test with excellent sensitivity can still generate more false positives than true ones once it meets a low-prevalence population. This analysis works through the arithmetic, draws on UK screening and lateral flow experience, and sets out the questions commissioners should ask before adoption.
Promising diagnostics and devices rarely fail on the science alone. They stall in the gaps between prototype, regulation and NHS adoption. Here are seven recurring bottlenecks, with UK-specific warning signs and questions to ask before budgets are committed.